Last reviewed · How we verify
AZD9977, oral suspension
At a glance
| Generic name | AZD9977, oral suspension |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects (PHASE1)
- Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects (PHASE1)
- A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects (PHASE1)
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males (PHASE1)
- A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects (PHASE1)
- A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD9977, oral suspension CI brief — competitive landscape report
- AZD9977, oral suspension updates RSS · CI watch RSS
- AstraZeneca portfolio CI